| Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has active development programs which comprises of ongoing phase 2 trial of HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; ongoing phase 2 trial of novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E. |
|
